Dihydroergotamine mesilate intranasal - Satsuma Pharmaceuticals
Alternative Names: Atzumi; Dihydroergotamine mesilate - Satsuma Pharmaceuticals; Dihydroergotamine mesylate - Satsuma Pharmaceuticals; STS-101; TO-2070Latest Information Update: 14 Nov 2025
At a glance
- Originator Shin Nippon Biomedical Laboratories
- Developer Satsuma Pharmaceuticals
- Class Antimigraines; Ergotamines; Mesylates; Small molecules
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Migraine